

Company Number: 631552

**Xenogenix (IE) Limited**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 30 April 2025**

**Xenogenix (IE) Limited**  
**CONTENTS**

|                                   | <b>Page</b> |
|-----------------------------------|-------------|
| Directors and Other Information   | 3           |
| Balance Sheet                     | 4           |
| Notes to the Financial Statements | 5 - 7       |

**Xenogenix (IE) Limited**  
**DIRECTORS AND OTHER INFORMATION**

|   |   |
|---|---|
| <b>Directors</b>                              | Dwayne Schnepel<br>Michael Mackay Mcintyre                            |
| <b>Company Secretary</b>                      | CPC Business Services Limited   |
| <b>Company Number</b>                         | 631552  |
| <b>Registered Office and Business Address</b> | 1 Terenure Place<br>Terenure<br>Dublin 6W                             |
| <b>Accountants</b>                            | Cronin Financial Limited<br>1 Terenure Place<br>Terenure<br>Dublin 6W |
| <b>Bankers</b>                                | Revolut Business  |

**Xenogenix (IE) Limited**  
**BALANCE SHEET**  
as at 30 April 2025

|   | Notes | 2025<br>€       | 2024<br>€       |
|---|-------|-----------------|-----------------|
| <b>Current Assets</b>                                 |       |                 |                 |
| Debtors   | 5     | 41,410          | 35,784          |
| Cash at bank and in hand                              |       | 12,394          | 8,946           |
|   |       | <u>53,804</u>   | <u>44,730</u>   |
| <b>Creditors: amounts falling due within one year</b> | 6     | <u>(37,875)</u> | <u>(50,106)</u> |
| <b>Net Current Assets/(Liabilities)</b>               |       | <u>15,929</u>   | <u>(5,376)</u>  |
| <b>Total Assets less Current Liabilities</b>          |       | <u>15,929</u>   | <u>(5,376)</u>  |
| <b>Creditors:</b>                                     |       |                 |                 |
| amounts falling due after more than one year          | 7     | -               | (46,413)        |
| <b>Net Assets/(Liabilities)</b>                       |       | <u>15,929</u>   | <u>(51,789)</u> |
| <b>Capital and Reserves</b>                           |       |                 |                 |
| Called up share capital presented as equity           |       | 100             | 100             |
| Retained earnings                                     | 8     | 15,829          | (51,889)        |
| <b>Shareholders' Funds/(Deficit)</b>                  |       | <u>15,929</u>   | <u>(51,789)</u> |

We as Directors of Xenogenix (IE) Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,


(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014.

Approved by the board on 11 March 2026 and signed on its behalf by:

Dwayne Schnepel  
Director



Michael Mackay McIntyre  
Director



# Xenogenix (IE) Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

### 1. General Information

Xenogenix (IE) Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 631552. The registered office of the company is 1 Terenure Place, Terenure, Dublin 6W.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### Statement of compliance

#### Basis of preparation

The Financial Statements are prepared on the going concern basis, under the historical cost convention and comply with the financial reporting standards of the Financial Reporting Council including 'The Financial Reporting Standard applicable to the Micro-Entities Regime – 'FRS 105', the Companies Act 2014.

The financial Statements have been presented in Euro (€) which is also the functional currency of the company.

#### Turnover

Turnover is recognised to the extent that the company obtains the right to consideration in exchange for its performance. Turnover comprises the fair value of consideration received and receivable exclusive of value added tax and after discounts and rebates.

Where the consideration receivable in cash or cash equivalents is deferred, and the arrangement constitutes a financing transaction, the fair value of the consideration is measured as the present value of all future receipts using the imputed rate of interest.

Turnover from the provision of services is recognised in the accounting period in which the services are rendered and the outcome of the contract can be estimated reliably. The company uses the percentage of completion method based on the actual service performed as a percentage of the total services to be provided.

#### Cash at bank and on hand

Cash and at bank and on hand include cash on hand, demand deposits and other term highly liquid investments regardless of maturity. Bank overdrafts are shown within borrowings in current liabilities on the balance sheet.

#### Creditors and accruals

Creditors and accruals are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities.

Creditors and accruals including amounts owed to group companies are recognised initially at transaction price (including transaction costs). For trade creditors where the payment is beyond normal credit terms it is held at the present value of all future payments using the imputed rate of interest or the cash price for the goods or services where material. Where loans are advanced it is carried at the transaction price (including transactions cost where material) regardless of whether a financing arrangement exists. Subsequently these are measured at transaction price less transaction costs not yet recognised, plus any unwinding of the discount on transactions initially recognised at present value/cash value, less repayments, plus advances. Transaction costs including any amounts deferred on purchases where payment is deferred beyond normal credit terms are released to the profit and loss on a straight line basis over the length of the contract.

#### Trade and other debtors

Trade and other debtors including amounts owed from group companies are recognised initially at transaction price (including transaction costs). For trade debtors where the payment is beyond normal credit terms it is held at the present value of all future payments using the imputed rate of interest or the cash price for the goods or services where material. Where loans are advanced it is carried at the transaction price (including transaction costs where material) regardless of whether a financing arrangement exists. Subsequently all trade and other debtors are measured at transaction price plus transaction costs not yet recognised, plus any unwinding of the discount on transactions initially recognised at present value/cash value, less repayments, plus advances and less any provision for impairment. Transaction costs including any amounts deferred on sales where receipt is deferred beyond normal credit terms are released to the profit and loss on a straight line basis over the length of the contract. A provision for impairment of trade debtors is established when there

**Xenogenix (IE) Limited****NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**

for the financial year ended 30 April 2025

is objective evidence that the company will not be able to collect all amounts due according to the original terms of receivables. The amount of the provision is the difference between the asset's carrying amount and the estimated future cash flows. All movements in the level of the provision required are recognised in the profit and loss.

**Taxation**

Current tax is calculated on the profits of the period. Current tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the balance sheet date.

Current taxation assets and liabilities are not discounted.

Deferred tax is not recognised.

**Foreign currencies**

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions or the contract rate.

At each period end foreign currency monetary items are translated using the closing rate or the contract rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction.

All foreign exchange gains and losses are presented in the profit and loss account within 'Other expenses'.

**Ordinary share capital**

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

|   |               |                |
|---|---------------|----------------|
| <b>3. Operating profit/(loss)</b>   | <b>2025</b>   | <b>2024</b>    |
|   | €             | €              |
| <b>Operating profit/(loss) is stated after charging/(crediting):</b>                                      |               |                |
| Loss/(profit) on foreign currencies   | <u>729</u>    | <u>(2,025)</u> |
| <b>4. Employees</b>   |               |                |
| The average monthly number of employees, including directors, during the financial year was 3 (2024 - 3). |               |                |
| <b>5. Debtors</b>   | <b>2025</b>   | <b>2024</b>    |
|   | €             | €              |
| Trade debtors   | 10,981        | 35,783         |
| Amounts owed by related parties   | 30,429        | -              |
| Taxation  | -             | 1              |
|   | <u>41,410</u> | <u>35,784</u>  |
| <b>6. Creditors</b>   | <b>2025</b>   | <b>2024</b>    |
| <b>Amounts falling due within one year</b>  | €             | €              |
| Trade creditors   | 799           | 3,188          |
| Taxation  | 30,826        | 35,900         |
| Accruals  | 6,250         | 11,018         |
|   | <u>37,875</u> | <u>50,106</u>  |
| <b>7. Creditors</b>   | <b>2025</b>   | <b>2024</b>    |
| <b>Amounts falling due after more than one year</b>   | €             | €              |
| Amounts owed to related parties   | <u>-</u>      | <u>46,413</u>  |

**Xenogenix (IE) Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 30 April 2025

**8. Profit and loss account**

|                                      | 2025<br>€            | 2024<br>€              |
|--------------------------------------|----------------------|------------------------|
| At 1 May 2024                        | (51,889)             | 656                    |
| Profit/(loss) for the financial year | <u>67,718</u>        | <u>(52,545)</u>        |
| At 30 April 2025                     | <u><u>15,829</u></u> | <u><u>(51,889)</u></u> |

**10. Post-Balance Sheet Events**

There have been no significant events affecting the company since the financial year-end.

**11. Controlling party**

The Company incorporated in Ireland with a registered office at 1 Terenure Place, Terenure, Dublin 6W. The ultimate controlling party is Xenogenix Limited

**12. Approval of financial statements**

The financial statements were approved and authorised for issue by the board of directors on 11 March 2026.